Trastuzumab deruxtecan in advanced breast cancer patients with brain metastases or leptomeningeal metastases

•Trastuzumab deruxtecan showed superior intracranial overall response rate (ORR) and median progression-free survival (mPFS) than controls in both stable and active brain metastases.•DEBBRAH, TUXEDO-1, and DESTINY-Breast 12 confirm durable intracranial activity in brain metastases with trastuzumab d...

Full description

Saved in:
Bibliographic Details
Published inCancer pathogenesis and therapy
Main Authors Liu, Jinsong, Quan, Liuliu, Sang, Die, Guan, Xiao, Dou, Min, Yue, Jian, Yuan, Peng
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.05.2025
Online AccessGet full text

Cover

More Information
Summary:•Trastuzumab deruxtecan showed superior intracranial overall response rate (ORR) and median progression-free survival (mPFS) than controls in both stable and active brain metastases.•DEBBRAH, TUXEDO-1, and DESTINY-Breast 12 confirm durable intracranial activity in brain metastases with trastuzumab deruxtecan.•Real-world ROSET-BM data reported median overall survival (OS, 27.0 months) and mPFS (14.6 months) in active BM, reinforcing T-DXd efficacy.•In leptomeningeal metastases (LM) cohorts, T-DXd achieved clinical benefit rate (71.4–100%), mOS (10.4–13.3 months), and mPFS (8.9–17.5 months) across studies.•For active BM, local intervention plus T-DXd (or tucatinib combination) is recommended based on efficacy stratification.
ISSN:2949-7132
2949-7132
DOI:10.1016/j.cpt.2025.05.003